ArticleDiabetology & metabolic syndrome2025
Understanding the causal effects and heterogeneity between metabolic syndrome and lung function: a nationwide prospective cohort study in China.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMetabolic syndrome (MetS) has been widely recognized as a risk factor for lung function. However, the evidence regarding the causal effect of MetS on lung function is limited, and it differs according to multidimensional individual characteristics. This study sought to investigate the causal effects and heterogeneity in the association between MetS and lung function through the development and validation of causal models.
methodsThis cohort study included adults from the China Health and Retirement Longitudinal Study (CHARLS) aged ≥ 45 years. We applied propensity score overlap weighting to balance baseline characteristics. The CausalForestDML model was used to estimate the causal and heterogeneous treatment effects, and SHapley Additive exPlanations analysis was implemented to explain the importance of features. Model evaluation was conducted using total operating characteristic (TOC) curves and QINI curves, and a heterogeneous analysis placebo test was conducted to verify the robustness of the model.
resultsOver the two years, 6,468 participants were included in our analysis, of which 4,498 (69.5%) had MetS. After applying overlap weighting, MetS exposure demonstrated a significant adverse causal effect on the peak expiratory flow as a percentage of predicted value (PEF%pred) (average treatment effect = -4.20, p < 0.001), and all participants exposed to MetS demonstrated individual treatment effects below zero. The body mass index (BMI), baseline PEF%pred, high-density lipoprotein cholesterol (HDL-C), and triglyceride glucose (TyG) index were the most influential factors. Subgroup analysis found that subgroup 4 (HDL-C ≤ 53.544 mg/dl, male, baseline PEF%pred ≥ 86.499) demonstrated the worst conditional average treatment effect (CATE) (-5.10). The CausalForestDML model demonstrates strong performance in distinguishing subgroups with varying treatment effects, and the placebo test also supports the causal interpretation (p < 0.05).
conclusionsDespite heterogeneity across individuals, the adverse causal effects of MetS exposure on lung function are universal. Preventing and managing MetS is essential for safeguarding lung function. Such causal machine learning models could evolve into clinically useful tools for personalized treatment decisions in MetS.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.